Literature DB >> 18431228

Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study.

Cyrielle Alméras1, Vincent Foulongne, Valérie Garrigue, Ilan Szwarc, Fernando Vetromile, Michel Segondy, Georges Mourad.   

Abstract

BACKGROUND: BK virus nephropathy (BKVN) is a severe complication of renal transplantation, resulting in graft loss in >50% of cases. Because patients with BKV viremia are at high risk for developing BKVN, the aim of our study was to analyze whether early reduction of immunosuppression (IS) could prevent BKVN in viremic patients.
METHODS: BKV viruria was prospectively screened every 3 months by real-time polymerase chain reaction during the first year after transplantation in 123 consecutive renal transplant recipients. Plasma viral load was measured by polymerase chain reaction whenever viruria was positive; in viremic patients a graft biopsy was systematically performed and IS was reduced.
RESULTS: Viruria, viremia, and BKVN occurred in 48.8%, 10.5%, and 2.4% of patients, respectively. In the 13 patients with positive viremia, initial graft biopsy showed BKVN in two. After reduction of IS in patients without BKVN, viremia disappeared in 8 of 11, decreased in 2 of 11, and increased in one patient who eventually developed BKVN. In contrast, viremia remained positive in one patient with BKVN and disappeared in the second but renal function deteriorated in both of them. Initial viral load was higher in patients who developed BKVN.
CONCLUSION: Reduction of IS is probably an effective therapeutic option to clear viremia and prevent BKVN in viremic renal transplant patients.

Entities:  

Mesh:

Year:  2008        PMID: 18431228     DOI: 10.1097/TP.0b013e31816a33d4

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation.

Authors:  Thurid Ahlenstiel-Grunow; Lars Pape
Journal:  Pediatr Nephrol       Date:  2018-12-11       Impact factor: 3.714

Review 2.  Polyomavirus-associated nephropathy.

Authors:  Cristina Costa; Rossana Cavallo
Journal:  World J Transplant       Date:  2012-12-24

3.  BK Virus-Associated Nephropathy in Kidney Transplant Recipients.

Authors:  Jorge C Garces
Journal:  Ochsner J       Date:  2010

Review 4.  BK polyomavirus infection and nephropathy: the virus-immune system interplay.

Authors:  Nina Babel; Hans-Dieter Volk; Petra Reinke
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

5.  Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.

Authors:  Michael E Seifert; Muthukumar Gunasekaran; Timothy A Horwedel; Reem Daloul; Gregory A Storch; Thalachallour Mohanakumar; Daniel C Brennan
Journal:  J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 10.121

6.  BK Viremia among Iranian Renal Transplant Candidates.

Authors:  Manizheh Jozpanahi; Amitis Ramezani; Shahrzad Ossareh; Mohammad Banifazl; Anahita Bavand; Setareh Mamishi; Arezoo Aghakhani
Journal:  Iran J Pathol       Date:  2016

7.  Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.

Authors:  Thurid Ahlenstiel-Grunow; Lars Pape
Journal:  Pediatr Nephrol       Date:  2019-12-19       Impact factor: 3.714

Review 8.  Management of polyomavirus-associated nephropathy in renal transplant recipients.

Authors:  Dirk R J Kuypers
Journal:  Nat Rev Nephrol       Date:  2012-04-17       Impact factor: 28.314

Review 9.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

10.  BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results.

Authors:  K L Hardinger; M J Koch; D J Bohl; G A Storch; D C Brennan
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.